Formoterol/glycopyrrolate

Drug Profile

Formoterol/glycopyrrolate

Alternative Names: GFF MDI; Glycopyrrolate/formoterol; PT-003; PT001/PT005; PT003-GFF; PT005/PT001

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Dec 2016 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT02685293)
  • 17 Oct 2016 Pearl Therapeutics plans a phase III trial for Chronic obstructive pulmonary disease in Belgium (Inhalation) (NCT02937584)
  • 03 Sep 2016 Efficacy data from a phase I trial in Chronic obstructive pulmonary disease (In volunteers) presented at the Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top